Second-line therapy for castrate-resistant prostate cancer: A literature review

Despite a survival benefit in the first‐line treatment of castrate‐resistant prostate cancer (CRPC) with docetaxel, the prognosis remains limited. There are increasing options available for patients with CRPC in the second‐line setting, but there is currently little consensus regarding the optimal t...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2011-09, Vol.7 (3), p.212-223
Main Authors: KAO, S C-H, HOVEY, E, MARX, G
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
castrate-resistant prostate cancer
cytotoxic
Drug Resistance, Neoplasm
hormone therapy
Humans
Immunotherapy
Male
Neoplasms, Hormone-Dependent
Orchiectomy
Prostatic Neoplasms - surgery
Prostatic Neoplasms - therapy
Quality of Life
Retreatment
second-line chemotherapy
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite a survival benefit in the first‐line treatment of castrate‐resistant prostate cancer (CRPC) with docetaxel, the prognosis remains limited. There are increasing options available for patients with CRPC in the second‐line setting, but there is currently little consensus regarding the optimal treatment. There have been numerous phase II and retrospective studies examining second‐line options in CRPC, including retreatment with docetaxel, mitoxantrone, cyclophosphamide and carboplatin, which can be associated with meaningful responses in a significant minority of patients. In 2010 three randomized trials were published or presented which demonstrated a survival benefit in the second‐line setting. These included cabazitaxel compared with mitoxantrone, sipuleucel‐T (immunotherapy) and abiraterone acetate versus placebo. Ongoing research in the second‐line setting of CRPC to optimize treatment options, with the objectives of survival prolongation, improvement in quality of life and pain management, is still needed.
ISSN:1743-7555
1743-7563
DOI:10.1111/j.1743-7563.2011.01421.x